[Pharmacological treatment for stress urinary incontinence in prostate cancer].
Stress urinary incontinence (SUI) is a symptom appearing in both males and females. Pharmacological treatment has demonstrated to be effective for female SUI, but its role for treatment in males is controversial. This review evaluates the various types of drugs, their effects, and levels of efficacy in the studies.
Puyol
Miguel
M
Servicio de Urología, Hospital Sant Joan de Déu, 08760 Martorell Barcelona, España. 21789mpp@comb.cat
Collado
Argimiro
A
D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use; D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D000068736:Duloxetine Hydrochloride; D006801:Humans; D007099:Imipramine / Q000627:therapeutic use; D008297:Male; D011468:Prostatectomy / Q000009:adverse effects*; D011471:Prostatic Neoplasms / Q000601:surgery*; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D013876:Thiophenes / Q000627:therapeutic use; D014550:Urinary Incontinence, Stress / Q000188:drug therapy* / Q000209:etiology
D018759:Adrenergic Uptake Inhibitors; D000316:Adrenergic alpha-Agonists; D000318:Adrenergic beta-Agonists; D000068736:Duloxetine Hydrochloride; D007099:Imipramine; D017367:Selective Serotonin Reuptake Inhibitors; D013876:Thiophenes